ICML 2019 | Oral nanatinostat and valganciclovir for EBV-associated lymphomas

Pierluigi Porcu

Pierluigi Porcu, MD, Sidney Kimmel Cancer Center – Jefferson Health, Philadelphia, PA, speaking from the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland, explains the Phase Ib/II study of oral nanatinostat and valganciclovir in patients with EBV-associated lymphomas (NCT03397706).

Share this video